the role of preclinical models to identify novel therapeutics in rare cancers
DESCRIPTION
The Role of Preclinical Models to Identify Novel Therapeutics in Rare Cancers. Peter J. Houghton, Ph.D. St. Jude Children’s Research Hospital. How To Select New Agents for Clinical Trials? Rationale for the Pediatric Preclinical Testing Program (PPTP). 400 new drugs in development. - PowerPoint PPT PresentationTRANSCRIPT
The Role of The Role of Preclinical Models to Preclinical Models to
Identify Novel Identify Novel Therapeutics in Rare Therapeutics in Rare
CancersCancersPeter J. Houghton, Ph.D.Peter J. Houghton, Ph.D.
St. Jude Children’s St. Jude Children’s Research HospitalResearch Hospital
How To Select New Agents for How To Select New Agents for Clinical Trials? Clinical Trials?
Rationale for the Pediatric Preclinical Testing Rationale for the Pediatric Preclinical Testing Program (PPTP)Program (PPTP)
Drug Development Drug Development NCI/Industry/NCI/Industry/
AcademiaAcademia
Phase IPhase I
Phase IIPhase II
• Prioritization of agents for phase I
• Rational decisions to advance/stop development
• Potential to focus phase II trials• Potential to identify sensitive tumors
• Establish relevant models that encompass clinical heterogeneity
400 new drugs in development
Drug X Testing @ MTD
Panel A Panel B Panel C Panel D Panel E
Active in Model(s)?Full Dose
Response/PK
Orthotopic Models
Transgenic Models
Final Report
No
Yes
Yes
YesNo
Stage 1 Report
Other Tumor Models Available?
Houghton et al. Clin Cancer Res. (2002)Houghton et al. Clin Cancer Res. (2002)
Overview of the PPTP ScreenOverview of the PPTP Screen
6 neuroblastomas
Why Do Preclinical Why Do Preclinical Cancer Models Fail?Cancer Models Fail?
• Species Tolerance: Host tolerance leads to high Species Tolerance: Host tolerance leads to high systemic exposure to drug -overprediction. Low systemic exposure to drug -overprediction. Low tolerance leads to low systemic exposure, and tolerance leads to low systemic exposure, and underprediction of drug activity.underprediction of drug activity.
• Tumor models do not recapitulate human cancer at Tumor models do not recapitulate human cancer at the molecular levelthe molecular level
• Criteria for defining ‘activity’ is more stringent in clinical trialsCriteria for defining ‘activity’ is more stringent in clinical trials
• Preclinical tumor models do not encompass clinical heterogeneityPreclinical tumor models do not encompass clinical heterogeneity
• Clinical trials design ignores preclinical dataClinical trials design ignores preclinical data
Molecular Molecular Characterization of Characterization of
Xenograft Tumor ModelsXenograft Tumor Models• Pediatric Preclinical Testing Pediatric Preclinical Testing Program (PPTP)Program (PPTP) -Affymetrix -Affymetrix (U133A)(U133A) -SNP analysis -SNP analysis (100K)(100K) -CGH-CGH
• Pediatric Oncology Preclinical Pediatric Oncology Preclinical Protein-Tissue Array Project (POPP-Protein-Tissue Array Project (POPP-TAP)TAP) -cDNA arrays-cDNA arrays
-Tissue/Protein -Tissue/Protein arraysarrays
How well do xenograft tumors represent the respective How well do xenograft tumors represent the respective clinical disease?clinical disease?
•Tumor models do not recapitulate human cancer at Tumor models do not recapitulate human cancer at the molecular level the molecular level
KCNRKCNRASAS
Tumors Cluster Along Diagnostic Tumors Cluster Along Diagnostic TypeType
by Unsupervised Clustering by Unsupervised Clustering cDNA Array:cDNA Array: all 38,789 Good Quality Genesall 38,789 Good Quality Genes
RH1 ? EWSRH1 ? EWSRH6RH6
JHANJHAN
Javed Khan -POPP-TAP Javed Khan -POPP-TAP (subnitted)(subnitted)
SC/OrthotopicSC/Orthotopic
Identify Xenografts That Recapitulate the Identify Xenografts That Recapitulate the Tumors of Origin.Tumors of Origin.
MDS 38,789 genes of primary/xeno/cell line: EWS/NB/RMSMDS 38,789 genes of primary/xeno/cell line: EWS/NB/RMS
ANN trained on tumors predict ANN trained on tumors predict xenograftsxenografts
PPTP Lines-Rh41-Rh10-Rh28-Rh30-Rh36-Rh18
PPTP Lines-Rh41-Rh10-Rh28-Rh30-Rh36-Rh18
PPTP Lines-SK-N-AS-NB-1643-NB-1691-NB-1771-NB-EB-NB-SD-NB-1382
PPTP Lines-SK-N-AS-NB-1643-NB-1691-NB-1771-NB-EB-NB-SD-NB-1382
Panels of Xenograft TumorsPanels of Xenograft TumorsAccurately Reflect Clinical Accurately Reflect Clinical
ResponsivenessResponsiveness
Vincristine 44%Vincristine 44%Cyclophosphamide 50%Cyclophosphamide 50%Actinomycin D 25%Actinomycin D 25%
Topotecan 50% clinical responsesTopotecan 50% clinical responses
• Preclinical tumor models do not encompass clinical heterogeneityPreclinical tumor models do not encompass clinical heterogeneity
Comparison of Expression Comparison of Expression Profiles in Kidney Tumors and Profiles in Kidney Tumors and
Their Derived Xenografts ModelsTheir Derived Xenografts ModelsClustering using 543 best classifiers >1Present Clustering using 543 best classifiers >1Present
(Affymetrix U133A)(Affymetrix U133A)
CCSKCCSKFetal kidneyFetal kidneyHPLNRHPLNRWilmsWilmsXenograftXenograft
CCSKCCSKFetal kidneyFetal kidneyHPLNRHPLNRWilmsWilmsXenograftXenograft
Wilm’s Tumor Xenografts Cluster with Wilm’s Tumor Xenografts Cluster with Their Clinical SamplesTheir Clinical Samples
Chemosensitivity of Chemosensitivity of Kidney Tumor Kidney Tumor XenograftsXenografts
BMS247550
Link Expression Profiles to Link Expression Profiles to Chemosensitivity to Identify Chemosensitivity to Identify
Biomarkers of ResponseBiomarkers of Response
• Criteria for defining ‘activity’ is more stringent in clinical trialsCriteria for defining ‘activity’ is more stringent in clinical trials
Non-GBM Brain TumorsNon-GBM Brain Tumors Kidney TumorsKidney Tumors
Drug ResponseSJ-BT39 SJ-GBM2
BCNUVP-16CDDPTOPOTECANCPT-11TEMOZOLOMIDEVINCRISTINEMGI-114PS341DOXORUBICINCARBOPLATINDEPSIPEPTIDEBMS247550RII5777SU6668
umor Line OS-1 OS-2 OS-17 OS-21 OS-29 OS-31 OS-32 OS-33ncristine 4-11-05 4-11-05 4-11-05
toxan 4-11-05 4-11-05 4-11-05
ctinomycin 4-11-05 4-11-05 4-11-05
potecan 4-11-05 4-11-05
mozolomide 4-11-05
PT-11 4-11-05
G1-114 4-11-05
CNU 4-11-05 4-11-05 4-11-05
P-16 4-11-05 4-11-05 4-11-05
DDPARBOPOPLAT
XALIPLATxorubicin 4-11-05 4-11-05
-341 4-11-05
MS247550 4-11-05
R(111 ) 4-11-05 4-11-05
115777 4-11-05 4-11-05
psipeptide 4-11-05
AAG 4-11-05
-713489 4-11-05 4-11-05
HA 4-11-05
xol 4-11-05 4-11-05 4-11-05
BT-751 4-11-05 4-11-05 4-11-05
AD 001CI-779RF1042
GlioblastomaGlioblastomaOsteosarcomaOsteosarcoma
mor Line Rh10 Rh12 Rh18 Rh28 Rh30 Rh35 Rh36 Rh39 IRS56 IRS68 Rh65 Rh66stology ARMS ERMS ERMS ARMS ARMS ERMS ERMS ERMS ARMS ARMSncristinetoxanctinomycinpotecanmozolomide
PT-11PAMG1-114
CNUP-16DDP
xorubicin-341
MS247550R(111)115777psipeptideAAG-713489HAxol
BT-751AD001D1839
6668
RhabdomyosarcomaRhabdomyosarcomaNeuroblastomaNeuroblastoma
Linking ChemosensitivtyLinking ChemosensitivtyTo Expression ProfilingTo Expression Profiling
Identifying BiomarkersIdentifying BiomarkersFor Predicting Drug-For Predicting Drug-Responsive PopulationsResponsive Populations
----
----
----
----
----
----
----
----
--T
otal
no
of r
ecor
ds:
Col
umns
incl
uded
: lo
g2(d
ap08
6-u1
33v2
_Sig
nal),
Z-s
core
s (1
), lo
g2(d
ap11
0-u1
33v2
_Sig
nal),
Z-
scor
es (
1),
log2
(dap
113-
u133
v2_2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
111-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
121-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
073-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap07
8-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
077-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
074-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
075-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap07
1-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
070-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
069-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
084-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap07
9-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
085-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
083-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
081-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap07
6-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
082-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
068-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
072-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap08
0-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
092-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
093-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
103-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap10
1-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
102-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
106-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
100-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap09
9-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
104-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
105-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
089-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap09
5-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
094-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
096-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
097-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap09
8-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
091-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
090-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
109-
u133
v2_S
igna
l), Z
-sc
ores
(1)
, lo
g2(d
ap10
8-u1
33v2
_Sig
nal),
Z-s
core
s (1
),
log2
(dap
112-
u133
v2_S
igna
l), Z
-sco
res
(1),
log2
(dap
107-
u133
v2_S
igna
l), Z
-sco
res
(1)
Em
pty
valu
es r
epla
ced
by:
0
Clu
ster
ing
met
hod:
UP
GM
A (
unw
eigh
ted
aver
age)
Sim
ilarit
y m
easu
re:
Euc
lidea
n di
stan
ceO
rder
ing
func
tion:
Ave
rage
val
ue
Hierarchical Clustering Trusted samples based on Hierarchical Clustering Trusted samples based on LogSignal CV 0.5 Max-Min>=100 at least 3 Present LogSignal CV 0.5 Max-Min>=100 at least 3 Present
(1113 probesets)(1113 probesets)
ALL
-19
BT
-50
NB
-EB
c1
D-4
56
OS
-2
BT
-28
OS
-164
OS
-166
OS
-187
SK
NE
P
EW
-8
EW
-5
WT
-12
WT
-14
WT
-13
WT
-11
WT
-10
Rh3
6
Rh1
0
Rh6
5
Rh4
1
Rh2
8E
W-1
Rh3
0B
T-2
9
WT
-16
Rh1
8
BT
-46
CH
L-79
NB
-169
1
SK
-N-A
SN
B-1
771
NB
-SD
NB
-164
3
NB
-132
BT
-45
BT
-39
SJ-
GB
M2
BT
-56
D-2
12
BT
-41
BT
-36
OS
-17
OS
-21
OS
-1
Group 1 versus Group 2 Osteosarcomas( Probesets >4-fold Ttest FDR<0.01)
OS#1 OS#2
keratin 18keratin 19cadherin 1, type 1, E-cadherin (epithelial)
fibronectin 1 /// fibronectin 1carboxypeptidase EIntegrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II)
BT-29WT-11WT-13WT-16SKNEPWT-14WT-10WT-12EW1EW5EW8(Rh1)Rh10Rh18Rh28Rh30Rh41Rh36Rh65BT-28BT-31BT-32BT-45BT-36BT-41BT-46BT-50SJ-GBM2SJ-BT39D645D456SJ-BT56D212NB-SDNB-1771NB-1691NB-EBc1CHLA-79NB-1643NB-1382SK-N-ASOS-1OS-2OS-17OS164OS166OS187OS-21OS160ALL-2ALL-3ALL-4ALL-7ALL-8ALL-16ALL-17ALL-19ALL-10ALL-11
0501
0502
0503
0504
0505
0506
0507
0508
0
1
2
3
4
Not Determined
Neuroblastoma Osteosarcoma ALL
Progressive Disease
Kidney/Rhabdoid Sarcoma Non-GBM Brain Tumor Glioblastoma
Stable Disease
Partial Response
Complete Response
Maintained Complete Response
Chemosensitivity of Tumors in the PPTP PanelChemosensitivity of Tumors in the PPTP Panel
VincristineVincristine
The PPTPThe PPTP
• Richard Gorlick (osteosarcoma)Richard Gorlick (osteosarcoma)• John Maris (neuroblastoma)John Maris (neuroblastoma)• Henry Friedman (glioblastoma)Henry Friedman (glioblastoma)• Richard Lock (ALL)Richard Lock (ALL)• Pat Reynolds (in vitro testing)Pat Reynolds (in vitro testing)• Malcolm Smith (CTEP)Malcolm Smith (CTEP)• Javed Khan (NCI)Javed Khan (NCI)• Geoff Neale (St. Jude)Geoff Neale (St. Jude)• Chris Morton (St. Jude; coordinator)Chris Morton (St. Jude; coordinator)
ThanksThanks
Drug X Testing @ MTD
Panel A Panel B Panel C Panel D Panel E
Active in Model(s)?Full Dose
Response/PK
Orthotopic Models
Transgenic Models
Final Report
No
Yes
Yes
YesNo
Stage 1 Report
Other Tumor Models Available?
Houghton et al. Clin Cancer Res. (2002)Houghton et al. Clin Cancer Res. (2002)
Overview of the PPTP ScreenOverview of the PPTP Screen
Model Systems for Drug Model Systems for Drug SelectionSelection
Drug Development Drug Development NCI/Industry/NCI/Industry/
AcademiaAcademia
Phase IPhase I
Phase IIPhase II
•Rational decisions to Rational decisions to advance/stop development advance/stop development based on PK parametersbased on PK parameters•Potential to focus phase Potential to focus phase II trialsII trials•Potential to identify Potential to identify biomarkers for patient biomarkers for patient selectionselection
•Relevant models (panels).Relevant models (panels).-molecular -molecular
identityidentity --encompass clinical encompass clinical heterogeneityheterogeneity
Brain Tumor Panel (glioblastoma) Duke University School of Medicine SJ -GBM2 Glioblastoma SJ -BT39 Glioblastoma D645 Glioblastoma D456 Glioblastoma SJ -BT56 (extended panel) Glioblastoma D212 (extended panel) Glioblastoma Brain Tumor Panel (non-glioblastoma)
St. J ude Children’s Research Hospital
BT-28 Medulloblastoma (diagnosis) BT-31 Anaplastic medulloblastoma (diagnosis) BT-32 Medulloblastoma (diagnosis) BT-45 Medulloblastoma (diagnosis) BT-36 Anaplastic Ependymoma (diagnosis) BT-41 Ependymoma (relapse) BT-46 (extended panel) Medulloblastoma (diagnosis) BT-50 (extended panel) Medulloblastoma (diagnosis) Sarcoma Panel St. J ude Children’s Research Hospital EW1 Ewing sarcoma (relapse) EW5 Ewing sarcoma (diagnosis) EW8 Ewing sarcoma RH10 Rhabdomyosarcoma, alveolar (relapse) RH18* Rhabdomyosarcoma, embryonal (diagnosis) RH28 Rhabdomyosarcoma, alveolar (diagnosis) RH30* Rhabdomyosarcoma, alveolar (diagnosis) RH41* Rhabdomyosarcoma, alveolar (relapse) RH36 (extended panel) Rhabdomyosarcoma, embryonal (relapse) RH65 (extended panel) Rhabdomyosarcoma, alveolar (relapse) Osteosarcoma panel Albert Einstein College of Medicine OS-1 Osteosarcoma (primary/untreated) OS-2 Osteosarcoma (primary/untreated) OS-17 Osteosarcoma (primary/untreated) OS-164 Osteosarcoma (primary/previously treated) OS-166 Osteosarcoma (osteoblastic primary/relapse) OS-187 Osteosarcoma (primary/untreated) OS-21 (extended panel) Osteosarcoma (primary/untreated) OS-160 (extended panel) Osteosarcoma (lung metastasis/r elapse)
Tumor Panel: 9-10-05
Acute Lymphoblastic Leukemia panel
Children’s Cancer I nstitute of Australia
ALL-2 c-ALL /Relapse 3 (CR1 = 30 mos) ALL-3 Pre-B ALL /Diagnois (CR1 = 38 mos) ALL-4 Ph+ ALL /Diagnosis (CR1 = 10 mos) ALL-7 Biphenotypic /Diagnosis (CR1 = 7 mos) ALL-8 T-ALL /Relapse 1 (CR1 = 17 mos) ALL-16 T-ALL /Diagnosis (CR1 = 103+ mos) ALL-17 c-ALL /Diagnosis (CR1 = 25 mos) ALL-19 c-ALL /Relapse 1 (CR1 = 4 mos) ALL-10 (extended panel) c-ALL /Diagnosis (CR1 = 57+ mos) ALL-11 (extended panel) c-ALL /Diagnosis (CR1 = 120+ mos) Neuroblastoma panel Children’s Hospital of Philadelphia NB-SD MYCN amplified (previously treated) NB-1771 MYCN amplified (diagnosis) NB-1691 MYCN amplified (relapse) NB-EBc1* Not MYCN amplified (relapse) CHLA-79 Not MYCN amplified (relapse) NB-1643* MYCN amplified (diagnosis) NB-1382 (extended panel) MYCN amplified (relapse) SK-N-AS (extended panel) Not MYCN amplified (diagnosis) Kidney/ rhabdoid tumor panel St. J ude Children’s Research Hospital BT-29 Atypical teratoid rhabdoid (CNS) (diagnosis) WT-14 Rhabdoid, kidney (relapse) WT-11 Wilms favorable histology (diagnosis) WT-13 Wilms diffuse anaplastic (diagnosis) WT-16 Rhabdoid, kidney (relapse) SKNEP Wilms diffuse anaplastic (relapse) WT-10 (extended panel) Wilms favorable histology (diagnosis) WT-12 (extended panel) Rhabdoid, kidney (diagnosis)
Tumor Panel: 9-10-05 (cont.)
Volcano: Group OS1 vs Group OS2